personalised treatment
Recently Published Documents


TOTAL DOCUMENTS

175
(FIVE YEARS 88)

H-INDEX

13
(FIVE YEARS 3)

2022 ◽  
Vol 11 (2) ◽  
pp. 311
Author(s):  
Massimiliano Salati ◽  
Andrea Spallanzani

Gastric and gastroesophageal junction adenocarcinoma (GEA) is still responsible for a huge health burden worldwide, being the second most common cause of cancer-related death globally [...]


2021 ◽  
Vol 11 ◽  
Author(s):  
Daniel Ren Yi Yap ◽  
Jolene Si Min Wong ◽  
Qiu Xuan Tan ◽  
Joey Wee-Shan Tan ◽  
Claramae Shulyn Chia ◽  
...  

BackgroundPeritoneal metastasis (PM) is a late-stage manifestation of intra-abdominal malignancies. The current standard of care indicates that cure can only be achieved with cytoreductive surgery (CRS) which is often indicated with concurrent adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC). However, the utility of HIPEC within subsets of PM is not fully understood. We seek to compare the effectiveness of HIPEC in improving peritoneal recurrence rates in PM of different origins.MethodsWe conducted a systematic review of trials on the PubMed, EMBASE, and Cochrane databases, last searched in August 2021. Biases were assessed using the Cochrane Collaboration’s tool for assessing the risk of bias in randomized trials as well as the Methodological Index for Non-Randomized Studies (MINORS) framework.Results7 gastric PM studies, 3 ovarian PM studies, and 3 colorectal PM studies were included. Recurrence-free survival was improved in the HIPEC + CRS cohort in 5 gastric trials but only 1 ovarian trial and none of colorectal origin.DiscussionOur findings indicate decent effectiveness of HIPEC in gastric PM, but limited utility in ovarian and colorectal PM. Limitations in the current literature are attributed to the paucity of data available, a lack of homogeneity and consideration of novel and personalised treatment regimens. We implore for further studies to be conducted with a focus on patient selection and stratification, and suggest a reframing of approach towards modern molecular and targeted therapeutic options in future studies of HIPEC.Systematic Review Registrationhttps://www.researchregistry.com/browse-the-registry#registryofsystematicreviewsmeta-analyses/registryofsystematicreviewsmeta-analysesdetails/60c1ffff0c1b78001e8efbe3/, identifier reviewregistry1166.


2021 ◽  
Vol 25 (3) ◽  
Author(s):  
Jacek Lorkowski ◽  
Elżbieta Szczygieł

On June 30, 2021, 23 years after its establishment, the activity of "Zdrowie" [Eng. Health] Rehabilitation Centre in Kraków came to an end. At the “Zdrowie” Rehabilitation Centre, this was done through appropriate personalised treatment, mainly rehabilitation, and since its inception, the centre had promoted not only the treatment of diseases, the consequences of traumatic injuries and the resulting disability, but most of all, their prevention. In 1998, as one of the first centres in Poland, the “Zdrowie” Rehabilitation Centre began routinely carrying out pedobarographic examinations, to an extent not found in other places at that time. Since 2006, photogrammetric testing has also been performed. What definitely distinguished the Centre, not only in Kraków, but also on the Polish medical market, was, among others, its scientific activity. Based on the Centre's professional and scientific achievements, sixteen M.A. one B.A, three doctoral dissertations, articles published in reputable journals with the Impact Factor (IF) index and scores from the Ministry of Science and Higher Education (MNiSW) or the Ministry of Science and Education (MNiE) were prepared.


Biomedicines ◽  
2021 ◽  
Vol 9 (11) ◽  
pp. 1610
Author(s):  
Jin Xu ◽  
Rebecca Green ◽  
Min Kim ◽  
Jodie Lord ◽  
Amera Ebshiana ◽  
...  

Background: physiological differences between males and females could contribute to the development of Alzheimer's Disease (AD). Here, we examined metabolic pathways that may lead to precision medicine initiatives. Methods: We explored whether sex modifies the association of 540 plasma metabolites with AD endophenotypes including diagnosis, cerebrospinal fluid (CSF) biomarkers, brain imaging, and cognition using regression analyses for 695 participants (377 females), followed by sex-specific pathway overrepresentation analyses, APOE ε4 stratification and assessment of metabolites’ discriminatory performance in AD. Results: In females with AD, vanillylmandelate (tyrosine pathway) was increased and tryptophan betaine (tryptophan pathway) was decreased. The inclusion of these two metabolites (area under curve (AUC) = 0.83, standard error (SE) = 0.029) to a baseline model (covariates + CSF biomarkers, AUC = 0.92, SE = 0.019) resulted in a significantly higher AUC of 0.96 (SE = 0.012). Kynurenate was decreased in males with AD (AUC = 0.679, SE = 0.046). Conclusions: metabolic sex-specific differences were reported, covering neurotransmission and inflammation pathways with AD endophenotypes. Two metabolites, in pathways related to dopamine and serotonin, were associated to females, paving the way to personalised treatment.


2021 ◽  
Vol 10 (3) ◽  
pp. 132-139
Author(s):  
Dominik Linz ◽  
Sander Verheule ◽  
Aaron Isaacs ◽  
Ulrich Schotten

Successful translation of research focussing on atrial arrhythmogenic mechanisms has potential to provide a mechanism-tailored classification and to support personalised treatment approaches in patients with AF. The clinical uptake and clinical implementation of new diagnostic techniques and treatment strategies require translational research approaches on various levels. Diagnostic translation involves the development of clinical diagnostic tools. Additionally, multidisciplinary teams are required for collaborative translation to describe genetic mechanisms, molecular pathways, electrophysiological characteristics and concomitant risk factors. In this article, current approaches for AF substrate characterisation, analysis of genes potentially involved in AF and strategies for AF risk factor assessment are summarised. The authors discuss challenges and obstacles to clinical translation and implementation into clinical practice.


2021 ◽  
Vol 1 (6) ◽  
pp. 116-122
Author(s):  
Al Ma Ariz Ridhuwan

Pharmacogenetics seeks to elucidate the variations in individual's genetic sequences in order to better understand the differences seen in pharmacokinetics, drug metabolism, and efficacy between patients. This area of research is rapidly accelerating, aided by the use of novel and more economical molecular technologies. A substantial evidence base is being generated with the hopes that in the future it may be used to generate personalised treatment regimens in order to improve patient comfort and safety and reduce incidences of morbidity and mortality.


Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4986
Author(s):  
Victoria Smith Arnesen ◽  
Andrea Gras Navarro ◽  
Martha Chekenya

Glioblastoma (GBM) is the most prevalent, aggressive primary brain tumour with a dismal prognosis. Treatment at diagnosis has limited efficacy and there is no standardised treatment at recurrence. New, personalised treatment options are under investigation, although challenges persist for heterogenous tumours such as GBM. Gene editing technologies are a game changer, enabling design of novel molecular-immunological treatments to be used in combination with chemoradiation, to achieve long lasting survival benefits for patients. Here, we review the literature on how cutting-edge molecular gene editing technologies can be applied to known and emerging tumour-associated antigens to enhance chimeric antigen receptor T and NK cell therapies for GBM. A tight balance of limiting neurotoxicity, avoiding tumour antigen loss and therapy resistance, while simultaneously promoting long-term persistence of the adoptively transferred cells must be maintained to significantly improve patient survival. We discuss the opportunities and challenges posed by the brain contexture to the administration of the treatments and achieving sustained clinical responses.


2021 ◽  
Vol 22 (19) ◽  
pp. 10420
Author(s):  
Tsz Wai Ngai ◽  
Gamal Ahmed Elfar ◽  
Pearlyn Yeo ◽  
Nicholas Phua ◽  
Jin Hui Hor ◽  
...  

Niclosamide is an oral anthelmintic drug, approved for use against tapeworm infections. Recent studies suggest however that niclosamide may have broader clinical applications in cancers, spurring increased interest in the functions and mechanisms of niclosamide. Previously, we reported that niclosamide targets a metabolic vulnerability in p53-deficient tumours, providing a basis for patient stratification and personalised treatment strategies. In the present study, we functionally characterised the contribution of the aniline 4′-NO2 group on niclosamide to its cellular activities. We demonstrated that niclosamide induces genome-wide DNA damage that is mechanistically uncoupled from its antitumour effects mediated through mitochondrial uncoupling. Elimination of the nitro group in ND-Nic analogue significantly reduced γH2AX signals and DNA breaks while preserving its antitumour mechanism mediated through a calcium signalling pathway and arachidonic acid metabolism. Lipidomics profiling further revealed that ND-Nic-treated cells retained a metabolite profile characteristic of niclosamide-treated cells. Notably, quantitative scoring of drug sensitivity suggests that elimination of its nitro group enhanced the target selectivity of niclosamide against p53 deficiency. Importantly, the results also raise concern that niclosamide may impose a pleiotropic genotoxic effect, which limits its clinical efficacy and warrants further investigation into alternative drug analogues that may ameliorate any potential unwanted side effects.


2021 ◽  
Vol 22 (18) ◽  
pp. 10018
Author(s):  
Sara Manzano ◽  
Alvaro Gutierrez-Uzquiza ◽  
Paloma Bragado ◽  
Angel M Cuesta ◽  
Carmen Guerrero ◽  
...  

C3G (RAPGEF1) is a guanine nucleotide exchange factor (GEF) for GTPases from the Ras superfamily, mainly Rap1, although it also acts through GEF-independent mechanisms. C3G regulates several cellular functions. It is expressed at relatively high levels in specific brain areas, playing important roles during embryonic development. Recent studies have uncovered different roles for C3G in cancer that are likely to depend on cell context, tumour type, and stage. However, its role in brain tumours remained unknown until very recently. We found that C3G expression is downregulated in GBM, which promotes the acquisition of a more mesenchymal phenotype, enhancing migration and invasion, but not proliferation. ERKs hyperactivation, likely induced by FGFR1, is responsible for this pro-invasive effect detected in C3G silenced cells. Other RTKs (Receptor Tyrosine Kinases) are also dysregulated and could also contribute to C3G effects. However, it remains undetermined whether Rap1 is a mediator of C3G actions in GBM. Various Rap1 isoforms can promote proliferation and invasion in GBM cells, while C3G inhibits migration/invasion. Therefore, other RapGEFs could play a major role regulating Rap1 activity in these tumours. Based on the information available, C3G could represent a new biomarker for GBM diagnosis, prognosis, and personalised treatment of patients in combination with other GBM molecular markers. The quantification of C3G levels in circulating tumour cells (CTCs) in the cerebrospinal liquid and/or circulating fluids might be a useful tool to improve GBM patient treatment and survival.


Sign in / Sign up

Export Citation Format

Share Document